Each year in this country, physicians prescribe medications to treat ADHD in nearly 3 million children. The safety of these agents has been the subject of some debate.
Each year in this country, physicians prescribe medications to treat ADHD in nearly 3 million children. The safety of these agents has been the subject of some debate.
Here to discuss the issue of the cardiovascular safety of stimulants, atomoxetine, and alpha-agonists used to manage ADHD is Joan Daughton, MD, Assistant Professor of Child Psychiatry at the University of Nebraska Medical Center in Omaha. Dr Daughton is also Training Director of the Creighton-Nebraska Child and Adolescent Psychiatry Training Program and Post Pediatrics Portal Program at the University of Nebraska Medical Center.
Dr Daughton also details the essentials of a baseline assessment and cardiovascular evaluation before ADHD therapy is initiated and briefly reviews scientific statements issued jointly by the American Heart Association and American Academy of Pediatrics on the overall safety of medications to treat ADHD and specifically in children with underlying cardiovascular abnormalities.
ADHD Medications
References
• Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-1904. http://www.nejm.org/doi/full/10.1056/NEJMoa1110212. Accessed October 17, 2012.
• Treatment of ADHD in children with tics: a randomized controlled trial. Tourette's Syndrome Study Group. Neurology. 2002;58:527-536.
• Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;118;2407-2423.
• Erratum in: Circulation. 2009;120:e55-9.
Is ADHD associated with shorter-than-expected height?
October 10th 2023To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.
SDX/d-MPH safe and effective against pediatric ADHD
March 15th 2023In a recent study, positive safety and efficacy outcomes for serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH; Azstarys; KemPharm) were found in children aged 6 years and older with attention-deficit/hyperactivity disorder (ADHD).
ADHD medications do not significantly increase cardiovascular disease risk
January 16th 2023A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.
Prenatal benzodiazepine exposure not directly associated with ASD and ADHD
January 11th 2023A recent study found that while children exposed to benzodiazepine during pregnancy had a greater risk of developing autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), siblings without exposure saw similar risks of neurodevelopmental disorders.